Evidence map›Paper›PMID 40401444›Full record

ArticleHuman molecular genetics2025

Genome sequencing reveals CCDC88A variants in malformations of cortical development and immune dysfunction.

Johanna Lehtonen, Anna H Hakonen, Antti Hassinen, Sanne Iversen Lurås, Meri Kaustio, Virpi Glumoff, Francisca Hinrichsen, Weiwei Li, Anna-Maija Sulonen, Sanna Wickman and 9 more

Abstract read
In one paragraph

Article in Human molecular genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Johanna LehtonenCentre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo Science Park, Gaustadalléen 2, Oslo 0349, Norway.
Anna H HakonenDepartment of Clinical Genetics, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Topeliuksenkatu 32, Helsinki 00290, Finland.
Antti HassinenInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Biomedicum 2, Tukholmankatu 8, Helsinki 00290, Finland.
Sanne Iversen LuråsCentre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo Science Park, Gaustadalléen 2, Oslo 0349, Norway.
Meri KaustioInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Biomedicum 2, Tukholmankatu 8, Helsinki 00290, Finland.
Virpi GlumoffMedical Research Laboratory Unit, Faculty of Medicine, University of Oulu, Pentti Kaiteran katu 1, Oulu 90570, Finland.
Francisca HinrichsenCentre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo Science Park, Gaustadalléen 2, Oslo 0349, Norway.
Weiwei LiCentre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo Science Park, Gaustadalléen 2, Oslo 0349, Norway.
Anna-Maija SulonenInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Biomedicum 2, Tukholmankatu 8, Helsinki 00290, Finland.
Sanna WickmanDepartment of Pediatric Neurology, Hyvinkää Hospital, Helsinki and Uusimaa Hospital District, Sairaalankatu 1, Hyvinkää 05850, Finland.
Henrikki AlmusaInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Biomedicum 2, Tukholmankatu 8, Helsinki 00290, Finland.
Minttu PolsoInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Biomedicum 2, Tukholmankatu 8, Helsinki 00290, Finland.
Maarit PalomäkiDepartment of Radiology, Helsinki University Hospital, Stenbäckinkatu 9, Helsinki 00290, Finland.
Sirpa KivirikkoDepartment of Clinical Genetics, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Topeliuksenkatu 32, Helsinki 00290, Finland.
Kristiina AvelaDepartment of Clinical Genetics, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Topeliuksenkatu 32, Helsinki 00290, Finland.
Kaarina HeiskanenNew Children's Hospital, HUS, Helsinki University Hospital and University of Helsinki, Stenbäckinkatu 9, Helsinki 00290, Finland.
Vilja PietiäinenInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Biomedicum 2, Tukholmankatu 8, Helsinki 00290, Finland.
Kristiina AittomäkiDepartment of Medical and Clinical Genetics, University of Helsinki, Fabianinkatu 33, Helsinki 00100, Finland.
Janna SaarelaCentre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo Science Park, Gaustadalléen 2, Oslo 0349, Norway.

Funding

Finska LäkaresällskapetResearch Council of Norway #187615Research Council of Norway #96782
6 · The paper itself

Abstract

Malformations of cortical development (MCDs) encompass a diverse group of genetic and clinical disorders. Here, we aimed to determine a genetic etiology for two siblings manifesting MCD, microcephaly, epilepsy, intellectual disability, and susceptibility to infections. A missense variant (NM_018084:c.929A > C, p.Asp310Ala) and an intragenic deletion (exons 14-16) in CCDC88A were identified as compound heterozygous in patients by genome sequencing. Truncating homozygous CCDC88A variants are known to cause an ultra-rare syndrome manifesting with MCD, microcephaly, seizures, and severe neurological impairment. CCDC88A encodes girdin, which is essential for various cell functions, such as actin remodeling and cell proliferation. Western blot analysis showed that the missense variant allele was expressed in fibroblasts at a level compatible with a heterozygous allele, whereas a truncated protein from the deletion allele was barely detectable. Proliferation and wound-healing assays revealed that girdin-deficient fibroblasts proliferated faster and migrated slower than controls. High-content imaging highlighted girdin-deficient fibroblasts as smaller and their actin remodeling disrupted, leading to perinuclear accumulation of endolysosomal organelles. To confirm these cellular phenotypes resulted from girdin loss, CRISPR-Cas9 edited knockout models of healthy fibroblasts were created, replicating the observations in patient cells. Additionally, the siblings exhibited reduced monocytoid and plasmacytoid dendritic cells, suggesting compromised immunity due to girdin deficiency. In summary, the study describes the first case of a CCDC88A missense variant and intragenic deletion associated with MCD. It demonstrates altered immunity and girdin-related cellular changes, such as cell morphology and proliferation-migration dichotomy, in patient and knockout fibroblasts, reinforcing the pathogenic relevance of these variants.

Indexed as

Malformations of Cortical DevelopmentMicrofilament ProteinsVesicular Transport ProteinsCell ProliferationEpilepsyFemaleFibroblastsHumansIntellectual DisabilityMaleMicrocephalyMutation, MissenseWhole Genome SequencingCCDC88A protein, humanMicrofilament ProteinsVesicular Transport ProteinsactinopathyCCDC88Agirdinimmunodeficiencymalformations of cortical development

Identifiers

PMID40401444
PMCPMC12278729

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.